NUVL
Nuvalent, Inc.
Key Financials
Operating Income
$-414307000
↓ 47.8%
Net Income
$-425377000
↓ 63.1%
Total Liabilities
$164.4M
↑ 128.4%
EPS (Diluted)
$-5.85
↓ 48.9%
Shareholders' Equity
$1.2B
↑ 16.7%
Cash & Equivalents
$261.7M
↑ 79.7%
Operating Cash Flow
$-275209000.00
↓ 48.7%
Total Assets
$1.4B
↑ 23.7%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 15-12G | 7/27/2026 | View on SEC |
| SCHEDULE 13G/A | 7/17/2026 | View on SEC |
| 4 | 7/17/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
| 4 | 7/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | NUVL |
| Company Name | Nuvalent, Inc. |
| CIK | 1861560 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 508-446-2272 |